<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597662</url>
  </required_header>
  <id_info>
    <org_study_id>SUP-002</org_study_id>
    <nct_id>NCT00597662</nct_id>
  </id_info>
  <brief_title>Safety Study of Polylactide-Caprolactone-Trimethylenecarbonate Copolymer for Post-Operative Adhesion Prophylaxis</brief_title>
  <official_title>Safety Study of Polylactide-Caprolactone-Trimethylenecarbonate Copolymer for Post-Operative Adhesion Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare adhesion prophylaxis with&#xD;
      polylactide-caprolactone-trimethylenecarbonate copolymer to icodextrin 4% in terms of safety,&#xD;
      side effects and usability in addition to gaining early evidence of the effectiveness of&#xD;
      polylactide-caprolactone-trimethylenecarbonate copolymer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in visual analogue pain score on visit 8 after discharge minus visit 1 on admission</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of analgesia</measure>
    <time_frame>1, 2 and 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative pyrexia</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative infection</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for re-operation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysmenorrhoea</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspareunia</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constipation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhoea</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of adhesion prophylaxis</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability as assessed by surgeon</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Adhesions</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>polylactide-caprolactone-trimethylenecarbonate copolymer</intervention_name>
    <description>Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Icodextrin 4%</intervention_name>
    <description>1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-60 years&#xD;
&#xD;
          -  sex female&#xD;
&#xD;
          -  laparoscopic myomectomy indicated&#xD;
&#xD;
          -  ability and intention to conform to the study protocol&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  indication for laparotomy&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  additional surgical interventions&#xD;
&#xD;
          -  known or suspected intollerance or hypersensibility to the interventions&#xD;
&#xD;
          -  chronic pain&#xD;
&#xD;
          -  systemic corticoids or irradiation&#xD;
&#xD;
          -  alcohol abuse or other substance abuse&#xD;
&#xD;
          -  clinical signs of malignancy&#xD;
&#xD;
          -  psychiatric or neurological disease&#xD;
&#xD;
          -  participation in another clinical trial within 30 days&#xD;
&#xD;
          -  inability to understand the purpose of the trial or to conform to the study protocol&#xD;
&#xD;
          -  absence of written informed consent&#xD;
&#xD;
          -  inflammation of pelvic organs&#xD;
&#xD;
          -  presence of adhesions which lead to a conversion from laparoscopy to laparotomy&#xD;
&#xD;
          -  concurrent therapy with corticoids, anti-neoplastic agents or irradiation&#xD;
&#xD;
          -  maintenance therapy with non-steroidal anti-inflammatory drugs or analgesics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diethelm Wallwiener, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Universitäts-Frauenklinik Tübingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>January 9, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2008</study_first_posted>
  <last_update_submitted>June 9, 2008</last_update_submitted>
  <last_update_submitted_qc>June 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. D. Wallwiener</name_title>
    <organization>Universitäts-Frauenklinik Tübingen</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Icodextrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

